Spectrum Pharma (SPPI) To be Reimbursed for ZAEVALIN Based on Average Sales Price
More News related to SPPI
- Spectrum Pharma (SPPI) Phase 3 Apaziquone Enrollment Complete
- Spectrum Pharmaceuticals Announces Completion of Enrollment in One Apaziquone Phase 3 Pivotal Trial for Bladder Cancer Ahead of Schedule
- Spectrum Pharma (SPPI) Files $250M Mixed Shelf
- Spectrum Pharma (SPPI) and Handok Pharma Announce Plans for Apaziquone Development in South Korea
- Spectrum Pharmaceuticals and Handok Pharmaceuticals Announce Collaboration Agreement for Apaziquone in South Korea
More News related to Corporate News
- ZymoGenetics (ZGEN) Higher Ahead of Presentation
- Somaxon Pharmaceuticals (SOMX) Surges Ahead of FDA Action Date
- BioMarin Pharmaceutical (BMRN) Announces FDA Grants Orphan Drug Designation for 3,4-DAP
- FDA Approves Cymbalta (LLY) for Treatment of Generalized Anxiety Disorder
- Eurand N.V. (EURX) Announces Availability of ZENPEP
Spectrum Pharmaceuticals (NASDAQ: SPPI) today announced that the Centers for Medicare & Medicaid Services (CMS) finalized a policy to allow reimbursement for ZEVALIN (ibritumomab tiuxetan), a CD20-directed radiotherapeutic antibody, in the Hospital Outpatient Prospective Payment System, based on the Average Sales Price (ASP) methodology applicable to other injectable drugs and biologicals. This reimbursement methodology will go in to effect January 1, 2010.
"We are pleased with the CMS policy ruling, as it represents an important milestone toward establishing a consistent reimbursement standard for ZEVALIN," said Rajesh C. Shrotriya, MD, Chairman, Chief Executive Officer, and President of Spectrum Pharmaceuticals. "We believe that securing ASP methodology for ZEVALIN removes a significant historical barrier to its use. This ASP methodology has until now been widely used for injectable chemotherapy drugs and as such, there is high familiarity with this reimbursement standard."
Related Categories
Corporate NewsStocks Mentioned
-0.11Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
